

Cover Story
By Alexandria Carolan
At first glance, the United States Supreme Court’s 303 Creative LLC. v. Elenis ruling has nothing to do with health care—but, looking deeper, experts in oncology and law are sounding alarms that the decision can be used to discriminate against LGBTQ+ patients.
In Brief


Clinical Roundup


Trending Stories
- Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit - NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Bhattacharya cancels NIH all-hands meeting
- In the Headlines: “There’s no one to stand up for NCI right now.”
- Cyber-iconoclast Vinay Prasad named head of FDA’s CBER
An oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies - $180M in NCI grants have been terminated by Trump administration, systematic review finds